- Home
- CELH vs ROIV Comparison
CELH vs ROIV Comparison
Compare CELH & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CELH | ROIV |
|---|---|---|
| Founded | 2004 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.1B | 14.1B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CELH | ROIV |
|---|---|---|
| Price | $44.75 | $22.48 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 18 | 8 |
| Target Price | ★ $63.41 | $24.31 |
| AVG Volume (30 Days) | 5.9M | ★ 8.3M |
| Earning Date | 11-06-2025 | 02-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.13 | N/A |
| Revenue | ★ $2,125,838,000.00 | $20,329,000.00 |
| Revenue This Year | $83.38 | N/A |
| Revenue Next Year | $32.58 | $376.94 |
| P/E Ratio | $352.93 | ★ N/A |
| Revenue Growth | ★ 55.07 | N/A |
| 52 Week Low | $21.10 | $8.73 |
| 52 Week High | $66.74 | $23.47 |
Technical Indicators
Market Signals| Indicator | CELH | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 52.09 | 61.27 |
| Support Level | $40.33 | $21.60 |
| Resistance Level | $45.56 | $22.76 |
| Average True Range (ATR) | 1.64 | 0.87 |
| MACD | 0.67 | 0.05 |
| Stochastic Oscillator | 85.75 | 70.16 |
Price Performance
Historical ComparisonAbout CELH Celsius Holdings Inc.
Celsius Holdings plays in the energy drink subsegment of the global nonalcoholic beverage market, with 95% of revenue concentrated in North America. The firm now owns three energy drink brands: Celsius, Alani Nu, and Rockstar Energy. It dedicates its efforts to product innovation and marketing while outsourcing manufacturing and packaging to third-party co-packers and distribution to PepsiCo. The firm issued convertible preferred shares following PepsiCo's investments in 2022 and 2025, giving the latter an 11% stake in Celsius.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.